Show simple item record

dc.contributor.authorUrowitz, M B
dc.contributor.authorGladman, D D
dc.contributor.authorIbañez, D
dc.contributor.authorFortin, P R
dc.contributor.authorBae, S C
dc.contributor.authorGordon, C
dc.contributor.authorClarke, A
dc.contributor.authorBernatsky, S
dc.contributor.authorHanly, J G
dc.contributor.authorIsenberg, D
dc.contributor.authorRahman, A
dc.contributor.authorSanchez-Guerrero, J
dc.contributor.authorWallace, D J
dc.contributor.authorGinzler, E
dc.contributor.authorAlarcón, G S
dc.contributor.authorMerrill, J T
dc.contributor.authorBruce, I N
dc.contributor.authorSturfelt, G
dc.contributor.authorNived, O
dc.contributor.authorSteinsson, K
dc.contributor.authorKhamashta, M
dc.contributor.authorPetri, M
dc.contributor.authorManzi, S
dc.contributor.authorRamsey-Goldman, R
dc.contributor.authorDooley, M A
dc.contributor.authorVan Vollenhoven, R F
dc.contributor.authorRamos, M
dc.contributor.authorStoll, T
dc.contributor.authorZoma, A
dc.contributor.authorKalunian, K
dc.contributor.authorAranow, C
dc.date.accessioned2023-02-06T19:59:06Z
dc.date.available2023-02-06T19:59:06Z
dc.identifier.citationUrowitz MB, Gladman DD, Ibañez D, Fortin PR, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Wallace DJ, Ginzler E, Alarcón GS, Merrill JT, Bruce IN, Sturfelt G, Nived O, Steinsson K, Khamashta M, Petri M, Manzi S, Ramsey-Goldman R, Dooley MA, van Vollenhoven RF, Ramos M, Stoll T, Zoma A, Kalunian K, Aranow C. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012 Jan;64(1):132-7. doi: 10.1002/acr.20648. PMID: 21954226.en_US
dc.identifier.eissn2151-4658
dc.identifier.doi10.1002/acr.20648
dc.identifier.pmid21954226
dc.identifier.urihttp://hdl.handle.net/20.500.12648/8251
dc.description.abstractWe describe disease activity, damage, and the accrual of key autoantibodies in an inception systemic lupus erythematosus (SLE) cohort.
dc.description.abstractThe Systemic Lupus International Collaborating Clinics (SLICC) International Research Network, comprising 27 centers from 11 countries, has followed an inception cohort of SLE patients yearly according to a standardized protocol. Of these patients, 298 were followed for a minimum of 5 years and constitute the study population. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K) and damage was assessed using the SLICC/American College of Rheumatology Damage Index (SDI). Antinuclear antibody (ANA), anti-DNA, and anticardiolipin antibody (aCL) levels and lupus anticoagulant were assessed yearly. Descriptive statistics were generated and repeated-measures general linear models were used to evaluate SLEDAI-2K and SDI over time between whites and nonwhites.
dc.description.abstractOf the 298 patients, 87% were women, 55% were white, 12% were African American, 14% were Asian, 16% were Hispanic, and 2% were categorized as "other." At enrollment, the mean age was 35.3 years, the mean SLEDAI-2K score was 5.9, and the mean disease duration was 5.5 months. Mean SLEDAI-2K scores decreased in the first year and then remained low. SLEDAI-2K scores were significantly lower at each year in whites compared to nonwhites. Mean SDI scores increased progressively over 5 years; there was no significant difference between whites and nonwhites. As expected, ANA positivity was high and anti-DNA positivity was relatively low at enrollment, and both increased over 5 years. Although lupus anticoagulant increased slightly over 5 years, aCL positivity did not.
dc.description.abstractDisease activity in newly diagnosed patients decreases over their first 5 years, while damage increases. Antibody positivity ran variable courses over this period.
dc.language.isoenen_US
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.20648en_US
dc.rightsCopyright © 2012 by the American College of Rheumatology.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleEvolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleArthritis care & researchen_US
dc.source.volume64
dc.source.issue1
dc.source.beginpage132
dc.source.endpage7
dc.source.countryCanada
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-02-06T19:59:06Z
html.description.abstractWe describe disease activity, damage, and the accrual of key autoantibodies in an inception systemic lupus erythematosus (SLE) cohort.
html.description.abstractThe Systemic Lupus International Collaborating Clinics (SLICC) International Research Network, comprising 27 centers from 11 countries, has followed an inception cohort of SLE patients yearly according to a standardized protocol. Of these patients, 298 were followed for a minimum of 5 years and constitute the study population. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K) and damage was assessed using the SLICC/American College of Rheumatology Damage Index (SDI). Antinuclear antibody (ANA), anti-DNA, and anticardiolipin antibody (aCL) levels and lupus anticoagulant were assessed yearly. Descriptive statistics were generated and repeated-measures general linear models were used to evaluate SLEDAI-2K and SDI over time between whites and nonwhites.
html.description.abstractOf the 298 patients, 87% were women, 55% were white, 12% were African American, 14% were Asian, 16% were Hispanic, and 2% were categorized as "other." At enrollment, the mean age was 35.3 years, the mean SLEDAI-2K score was 5.9, and the mean disease duration was 5.5 months. Mean SLEDAI-2K scores decreased in the first year and then remained low. SLEDAI-2K scores were significantly lower at each year in whites compared to nonwhites. Mean SDI scores increased progressively over 5 years; there was no significant difference between whites and nonwhites. As expected, ANA positivity was high and anti-DNA positivity was relatively low at enrollment, and both increased over 5 years. Although lupus anticoagulant increased slightly over 5 years, aCL positivity did not.
html.description.abstractDisease activity in newly diagnosed patients decreases over their first 5 years, while damage increases. Antibody positivity ran variable courses over this period.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentRheumatologyen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalArthritis care & research


Files in this item

Thumbnail
Name:
Arthritis Care Research - 2011 ...
Size:
116.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2012 by the American College of Rheumatology.
Except where otherwise noted, this item's license is described as Copyright © 2012 by the American College of Rheumatology.